Scleral thinning after repeated intravitreal injections of antivascular endothelial growth factor agents in the same quadrant

Investigative Ophthalmology and Visual Science

Volumn 56, Issue 3, 2015, Pages 1894-1900

  Zinkernagel, Martin S ^a   Schorno, Petra ^a   Ebneter, Andreas ^a   Wolf, Sebastian ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Anterior segment OCT; Anti VEGF; Intravitreal injections; Retina; Sclera

Indexed keywords

AFLIBERCEPT; RANIBIZUMAB; HYBRID PROTEIN; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

ADULT; AGED; ANTERIOR EYE SEGMENT; ARTICLE; CLINICAL ARTICLE; CROSS-SECTIONAL STUDY; EYE AXIS LENGTH; FEMALE; HUMAN; HUMAN EXPERIMENT; IMAGE ANALYSIS; INTRAOCULAR PRESSURE; MALE; OPHTHALMOLOGY; PRIORITY JOURNAL; RETINA; RETROSPECTIVE STUDY; SCLERA DISEASE; SCLERAL THICKNESS; SCLERAL THINNING; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; TREATMENT OUTCOME; VERY ELDERLY; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; FOLLOW UP; INTRAVITREAL DRUG ADMINISTRATION; METABOLISM; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; PROCEDURES; SCLERA; VISUAL ACUITY; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MALE; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES; SCLERA; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84925307994     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.14-16204     Document Type: Article

References (26)

1. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–1431.
2. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology. 2009;116:57–65.
3. Varma R, Bressler NM, Suner I, et al. Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials. Ophthalmology. 2012;119:2108–2118.
4. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118:615–625.
5. Wong IY, Koizumi H, Lai WW. Enhanced depth imaging optical coherence tomography. Ophthalmic Surg Lasers Imaging. 2011;42 (suppl):S75–S84.
6. Taban M, Sharma S, Ventura AA, Kaiser PK. Evaluation of wound closure in oblique 23-gauge sutureless sclerotomies with visante optical coherence tomography. Am J Ophthalmol. 2009;147:101–107.
7. Lopez-Guajardo L, Benitez-Herreros J, Teus-Guezala M. Optical coherence tomography as a method for studying sutureless microincisional vitrectomy sclerotomies. Am J Ophthalmol. 2009;148:321–322, author reply 322–323.
8. Lala C, Framme C, Wolf-Schnurrbusch UE, Wolf S. Three-year results of visual outcome with disease activity-guided ranibizumab algorithm for the treatment of exudative age-related macular degeneration. Acta Ophthalmol. 2013;91:526–530.
9. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377–381.
10. Meek KM, Fullwood NJ. Corneal and scleral collagens–a microscopist’s perspective. Micron. 2001;32:261–272.
11. Watson PG, Young RD. Scleral structure, organisation and disease. A review. Exp Eye Res. 2004;78:609–623.
12. Olsen TW, Aaberg SY, Geroski DH, Edelhauser HF. Human sclera: thickness and surface area. Am J Ophthalmol. 1998; 125:237–241.
13. Lam A, Sambursky RP, Maguire JI. Measurement of scleral thickness in uveal effusion syndrome. Am J Ophthalmol. 2005;140:329–331.
14. Oliveira C, Tello C, Liebmann J, Ritch R. Central corneal thickness is not related to anterior scleral thickness or axial length. J Glaucoma. 2006;15:190–194.
15. Norman RE, Flanagan JG, Rausch SM, et al. Dimensions of the human sclera: thickness measurement and regional changes with axial length. Exp Eye Res. 2010;90:277–284.
16. Brodie FL, Ruggiero J, Ghodasra DH, Hui JZ, VanderBeek BL, Brucker AJ. Volume and composition of reflux after intravitreal injection. Retina. 2014;34:1473–1476.
17. Hoang QV, Jung JJ, Mrejen S, Freund KB. Influence of axial length and postinjection reflux on sustained intraocular pressure elevation as a result of intravitreal anti-vascular endothelial growth factor therapy. Retina. 2014;34:519–524.
18. Rodrigues EB, Meyer CH, Grumann A Jr, Shiroma H, Aguni JS, Farah ME. Tunneled scleral incision to prevent vitreal reflux after intravitreal injection. Am J Ophthalmol. 2007;143:1035–1037.
19. Myles ME, Neumann DM, Hill JM. Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis. Adv Drug Deliv Rev. 2005;57: 2063–2079.
20. Geroski DH, Edelhauser HF. Transscleral drug delivery for posterior segment disease. Adv Drug Deliv Rev. 2001;52:37–48.
21. Chen D, Lian Y, Cui L, Lu F, Ke Z, Song Z. Sutureless vitrectomy incision architecture in the immediate postoperative period evaluated in vivo using optical coherence tomography. Ophthalmology. 2010;117:2003–2009.
22. Falkenstein IA, Cheng L, Freeman WR. Changes of intraocular pressure after intravitreal injection of bevacizumab (avastin). Retina. 2007;27:1044–1047.
23. Choi DY, Ortube MC, McCannel CA, et al. Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib. Retina. 2011;31:1028–1035.
24. Kim JE, Mantravadi AV, Hur EY, Covert DJ. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol. 2008;146:930–934.
25. Downs JC, Ensor ME, Bellezza AJ, Thompson HW, Hart RT, Burgoyne CF. Posterior scleral thickness in perfusion-fixed normal and early-glaucoma monkey eyes. Invest Ophthalmol Vis Sci. 2001;42:3202–3208.
26. Lee SB, Geroski DH, Prausnitz MR, Edelhauser HF. Drug delivery through the sclera: effects of thickness, hydration, and sustained release systems. Exp Eye Res. 2004;78:599–607.